|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | Our Study | PRO-ACT (19) | Celecoxib Trial (40) |
| Total Number of Patients Included | 5030 | 10723 | 300 |
| Patients with records in ALSFRS score | 2753 | 4142 | 0 |
| Patients with records in ALSFRS-R score | 2277 | 3742 | 300 |
| Age/years | 55.4±11.5 | 56.3±11.7 | 54.7±12.0 |
| Percentage Male/% | 62.0 | 60.3 | 64.7 |
| Percentage Limb Onset/% | 72.0 | 69.3 | 82.3 |
| Percentage Bulbar Onset/% | 22.6 | 22.0 | 17.7 |
| Baseline ALSFRS-R score | 36.0±6.7 | 36.4±6.5 | 39.3±5.2 |
| Baseline FVC percentage/% | 78.0±18.2 | 85.0±22.7 | 84.6±15.9 |

Supplementary Table 2: Description of patient group characteristics utilised in our study compared to the PRO-ACT database as a whole and the celecoxib trial (40), our holdout validation dataset. Patients with records in ALSFRS score had their scores multiplied with 1.2 to scale with those with ALSFRS-R score.